HPS-061 - Pharmacoepidemiology of anti-HER2 ADC induced interstitial lung disease: Real-world data analysis based on the FAERS database

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-061
• By: WANG, Yanting (Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, China)
• Co-author(s): Mr. Di Du (Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
  Mr. Yuke Li (Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
  Dr Yanting Wang (National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)
  Ms. Suying Xu (Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
  Ms. Jun Yang (National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)
  Mr. Peng Zhan (Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China)
  Ms Hongmei Zheng (Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China)
  Ms. Yanna Zhu (Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China)
  
• Abstract:

  Introduction: Antibody-drug conjugates (ADCs) targeting human epidermal growth factor receptor 2 (HER2), such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1), have revolutionized the treatment of HER2-positive malignancies. However, interstitial lung disease (ILD), a potentially fatal complication associated with ADCs, remains..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login